Alzheimer's research preview: a brief look at an upcoming conference presentation on emerging gene-therapy findings and industry implications.
Key Takeaways
- Company received FDA IND clearance for the Alzheimer's gene therapy this month
- Dosing in adults with early Alzheimer's is expected in the second half of 2026
- GLP non-human primate data showed up to 75% brain tau reduction and favorable tolerability